Condition

Refractory Acute Myeloid Leukemia (3)

Recurrent Acute Myeloid Leukemia (2)

Recurrent Acute Lymphoblastic Leukemia (1)

Recurrent B Acute Lymphoblastic Leukemia (1)

Recurrent Mixed Phenotype Acute Leukemia (1)

Recurrent T Acute Lymphoblastic Leukemia (1)

Refractory Mixed Phenotype Acute Leukemia (1)

Therapy-Related Acute Myeloid Leukemia (1)

Overall Status

Recruiting (2)

Withdrawn (1)

Phase

early phase 1 (1)

n/a (1)

phase 2 (1)

Sponsor

Children's Oncology Group (1)

LLS PedAL Initiative, LLC (1)

Michael Boyiadzis (1)

Collaborator

National Cancer Institute (NCI) (2)

Children's Oncology Group (1)

Merck Sharp & Dohme LLC (1)

Intervention

biospecimen collection (1)

enasidenib (1)

enasidenib mesylate (1)

pembrolizumab (1)

Study Documents

Intervention Type

drug (2)

procedure (1)

Funder Type

Other (3)

Study Type

Interventional (3)

Refractory Acute Myeloid Leukemia

Showing NaN - NaN of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

The Pediatric Acute Leukemia Screening Trial - A Study to Test

Recruiting

Recurrent Acute Lymphoblastic Leukemia
+7 more

Biospecimen Collection

Birmingham, Alabama
+144 more

Jan 30, 2023

Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Canada, United States (Enasidenib, Enasidenib

Recruiting

Recurrent Acute Myeloid Leukemia
Refractory Acute Myeloid Leukemia

Enasidenib
Enasidenib Mesylate

Birmingham, Alabama
+17 more

Jun 21, 2021

Refractory Acute Myeloid Leukemia Trial in Pittsburgh (pembrolizumab)

Withdrawn

Refractory Acute Myeloid Leukemia

pembrolizumab

Pittsburgh, Pennsylvania

UPMC Hillman Cancer Center

Apr 17, 2019